

**VIVALIS TO PARTICIPATE IN MIDCAP EVENT
ON 22 AND 23 SEPTEMBER 2011**

Nantes, Lyon (France) – 15 September 2011: VIVALIS (NYSE Euronext Paris : VLS), a biopharmaceutical company, announces today its participation in the 11th edition of the MidCap Event, taking place next 22 and 23 of September 2011, in Paris, at Palais Brongniart.

VIVALIS participation in this Forum, which brings together the main investors specialized in mid capitalization values traded in the Paris stock exchange, corresponds to the company willingness to reinforce the relationship with investors and to increase its visibility vis-à-vis the financial community. The Midcap Event will, thus, be an opportunity for asset managers to meet VIVALIS managing team which will be pleased to provide them with an insight on the company projects. It is believed that these one to one meetings will offer an opportunity to comment on those relevant facts occurred during the year; notably VIVALIS will present its technological and commercial advances for 2010 and VIVALIS growth strategy for the future.

**Next financial press release: 2011 third-quarter sales
October 20, 2011, after NYSE Euronext market closing**

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in three main areas:

1. EB66[®] Cell Line:

VIVALIS offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). EB66[®] cell line based vaccines are currently in clinical trials in USA and in Japan. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales.

2. VIVAIScreenTM Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of fully human monoclonal antibodies are now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales.

3. 3D-Screen Drug Discovery Platform

VIVALIS performs discovery and development, up to pre-clinical evaluation, of original small chemical molecules identified with its proprietary platform, 3D-SCREEN. This unique screening platform is designed to identify original molecules that alter the three-dimensional structure of a target protein, thus modulating its biological function through an innovative mode of action. VIVALIS is building a portfolio of proprietary new chemical entities for the treatment of hepatitis-C virus infection. VIVALIS also proposes, on a fee for service basis, to develop ready to use customized 3D-Screen HTS assays directed against client's target protein of interest.

Based in Nantes & Lyon (France) and in Toyama (Japan) VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,500 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bioclusters and a member of the Japanese OKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

VIVALIS

Listed on Euronext Paris – Compartment B of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes



This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's registration document (document de référence), changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0) 1 44 71 94 91

Email : vivalis@newcap.fr